Literature DB >> 15208511

Neuropeptides in eating disorders.

David C Jimerson1, Barbara E Wolfe.   

Abstract

The past decade has witnessed a dramatic acceleration in research on the role of the neuropeptides in the regulation of eating behavior and body weight homeostasis. This expanding research focus has been driven in part by increasing public health concerns related to obesity and the eating disorders anorexia nervosa (AN) and bulimia nervosa (BN). Preclinical advances have been facilitated by the development of new molecular and behavioral research methodologies. With a focus on clinical investigations in AN and BN, this article reviews research on selected hypothalamic and gut-related peptide systems with prominent effects on eating behavior. Studies of the orexigenic peptides neuropeptide Y and the opioid peptides have shown state-related abnormalities in patients with eating disorders. With respect to gut-related peptides, there appears to be substantial evidence for blunting in the meal-related release of the satiety promoting peptide cholecystokinin in BN. Fasting plasma levels of the orexigenic peptide ghrelin have been found to be elevated in patients with AN. As discussed in this review, additional studies will be needed to assess the role of nutritional and body weight changes in neuropeptide alterations observed in symptomatic eating disorder patients, and to identify stable trait-related abnormalities in neuropeptide regulation that persist in individuals who have recovered from an eating disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15208511     DOI: 10.1017/s1092852900009603

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  8 in total

1.  The multimodal treatment of eating disorders.

Authors:  Katherine A Halmi
Journal:  World Psychiatry       Date:  2005-06       Impact factor: 49.548

Review 2.  Engineering endomorphin drugs: state of the art.

Authors:  Lawrence H Lazarus; Yoshio Okada
Journal:  Expert Opin Ther Pat       Date:  2012-01-04       Impact factor: 6.674

Review 3.  Interacting Neural Processes of Feeding, Hyperactivity, Stress, Reward, and the Utility of the Activity-Based Anorexia Model of Anorexia Nervosa.

Authors:  Rachel A Ross; Yael Mandelblat-Cerf; Anne M J Verstegen
Journal:  Harv Rev Psychiatry       Date:  2016 Nov/Dec       Impact factor: 3.732

4.  The Genetics of Anorexia Nervosa: Current Findings and Future Perspectives.

Authors:  Andrea Poyastro Pinheiro; Tammy Root; Cynthia M Bulik
Journal:  Int J Child Adolesc health       Date:  2009

5.  Serotonin-induced decrease of intracellular Ca(2+) release in platelets of bulimic patients normalizes during treatment.

Authors:  Lars Wöckel; Florian Daniel Zepf; Sabrina Koch; Anikó-Eva Meyer-Keitel; Martin H Schmidt
Journal:  J Neural Transm (Vienna)       Date:  2008-12-10       Impact factor: 3.575

6.  The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress.

Authors:  Michael Lutter; Ichiro Sakata; Sherri Osborne-Lawrence; Sherry A Rovinsky; Jason G Anderson; Saendy Jung; Shari Birnbaum; Masashi Yanagisawa; Joel K Elmquist; Eric J Nestler; Jeffrey M Zigman
Journal:  Nat Neurosci       Date:  2008-06-15       Impact factor: 24.884

7.  Is Serum BDNF Altered in Acute, Short- and Long-Term Recovered Restrictive Type Anorexia Nervosa?

Authors:  Jonas L Steinhäuser; Joseph A King; Friederike I Tam; Maria Seidel; Ronald Biemann; Marie-Louis Wronski; Daniel Geisler; Veit Roessner; Stefan Ehrlich
Journal:  Nutrients       Date:  2021-01-29       Impact factor: 5.717

Review 8.  The role of "mixed" orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa.

Authors:  Kvido Smitka; Hana Papezova; Karel Vondra; Martin Hill; Vojtech Hainer; Jara Nedvidkova
Journal:  Int J Endocrinol       Date:  2013-09-09       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.